SCTX
NASDAQScribe Therapeutics Inc.
Scribe Therapeutics Inc. (SCTX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for SCTX, including 2 press releases and news items. The most recent was published Nov 5, 2026.
SCTX rankings
News · 26 weeks2+100%
2026-05-172026-11-08
Mix290d
- Other2(100%)
Activity · 52 weeks22 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
2 items- PRScribe Therapeutics to Participate in Upcoming Healthcare Investor ConferencesALAMEDA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics" or "the Company") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that management will participate in the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation ConferenceBoston, MANov. 10, 2026 at 1:00 PM ETBenjamin Oakes, Ph.D., co-founder and Chief Executive Officer, will participate in a fireside chat. Stifel Healthcare ConferenceNew York, NYNov. 11, 2026 at 3:20 PM ETBenjamin Oakes,
- PRScribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026Late-breaking presentation will report long-term durability preclinical data for STX-1150, Scribe’s lead epigenetic silencing therapy for LDL cholesterol reduction now in clinical trials A second presentation will reveal enhanced potency and specificity preclinical data for STX-1200, Scribe’s gene editing program designed to lower lipoprotein(a) CEO to participate in the inaugural AHA Innovation Forum’s sessions on entrepreneurship and AI in cardiovascular innovation ALAMEDA, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics" or "the Company") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologi
SCTX FAQ
7 questionsWhat does Scribe Therapeutics Inc. do?
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design approach and nature's blueprint for improved cardiovascular health, Scribe's initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company's lead candidate, STX-1150, is a novel liver-targeted therapy designed...What is the latest news on SCTX?
In the last 30 days Quantisnow tracked 2 wire items for SCTX: 2 press releases and news items. The most recent was published on November 5, 2026.Where does SCTX stock trade?
Scribe Therapeutics Inc. (SCTX) is listed on NASDAQ.What sector and industry is SCTX in?
Scribe Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Scribe Therapeutics Inc. go public?
Scribe Therapeutics Inc. (SCTX) completed its IPO in 2026.What companies are similar to SCTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare SCTX side-by-side with any of them on Quantisnow.How can I track SCTX on Quantisnow?
Quantisnow aggregates Scribe Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SCTX to receive live email and push alerts on every new disclosure.